Prognostic Role of ACVRL1/ALK1 in the Development of Pulmonary Hypertension: A Systematic Review

Mehrasa, Parisa; Nikfar, Mozhdeh

doi:10.5281/zenodo.21968802

Prognostic Role of ACVRL1/ALK1 in the Development of Pulmonary Hypertension: A Systematic Review

Articles in Press

Document Type : Review Article

Authors

Parisa Mehrasa ¹

Mozhdeh Nikfar ²

¹ Assistant Professor of Pathology, Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

² Assistant Professor of Pulmonary Diseases, Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

https://doi.org/10.5281/zenodo.21968802

Abstract

Introduction: ACVRL1 (ALK1) mutations are critical drivers of pulmonary hypertension, significantly influencing endothelial dysfunction and vascular remodeling. Despite its clinical importance, the precise prognostic impact of ALK1 on disease progression remains insufficiently characterized across diverse populations. This systematic review aims to evaluate the prognostic role of ACVRL1/ALK1 in the development and outcomes of pulmonary hypertension.

Material and methods: This systematic review was conducted according to PRISMA guidelines to evaluate the prognostic role of ACVRL1/ALK1 in pulmonary hypertension. Eligible human studies were systematically identified from international and national databases, screened against predefined inclusion and exclusion criteria, and assessed for methodological quality. Data on study characteristics, sample size, mutation status, hemodynamic parameters, disease progression, survival, and clinical outcomes were extracted using a standardized approach.

Results: Synthesis of 11 studies (n=11; cohort, case-control, and genetic designs) confirms that ACVRL1/ALK1 mutations independently correlate with earlier disease onset and accelerated clinical decline. Carriers exhibited significantly worse hemodynamic profiles (e.g., higher pulmonary arterial pressures) and increased right ventricular strain compared to non-carriers. Qualitative synthesis indicates higher risk stratification scores and diminished survival rates, underscoring ACVRL1 as a pivotal genetic determinant of aggressive pulmonary hypertension phenotypes and poor clinical outcomes.

Conclusion: ACVRL1/ALK1 mutations serve as a critical prognostic biomarker in pulmonary hypertension, identifying a high-risk cohort characterized by early-onset disease and rapid hemodynamic deterioration. Incorporating ACVRL1 genotyping into clinical risk stratification is essential for optimizing surveillance and initiating aggressive, personalized therapeutic interventions. Future prospective multicenter trials are necessary to refine genotype-specific survival estimates and standardize long-term management protocols for this vulnerable patient population.

Graphical Abstract

Keywords

ACVRL1

ALK1

Pulmonary hypertension

Prognosis

Subjects

Health

[1] Humbert, M., Kovacs, G., Hoeper, M. M., et al. (2023). 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 61(1), 2200879.

[2] Shlobin, O. A., Adir, Y., Barbera, J. A., et al. (2024). Pulmonary hypertension associated with lung diseases. European Respiratory Journal, 64(3), 2401200.

[3] Nathan, S. D., Piccari, L., Abman, S. H., et al. (2025). Significance of pulmonary vascular dysfunction in chronic obstructive pulmonary disease. Pulmonary Circulation, 15(1), e70144.

[4] Hoeper, M. M., Dwivedi, K., Pausch, C., et al. (2022). Phenotyping of idiopathic pulmonary arterial hypertension: A registry analysis. The Lancet Respiratory Medicine, 10(10), 937–948.

[5] Syed, M., Humbert, M., Kovacs, G., & Sahay, S. (2025). Overlapping pulmonary hypertension phenotypes in smokers: A call to action. The Lancet Respiratory Medicine, 13(10), 867–870.

[6] Olsson, K. M., Corte, T. J., Kamp, J. C., et al. (2023). Pulmonary hypertension associated with lung disease: New insights into pathomechanisms, diagnosis, and management. The Lancet Respiratory Medicine, 11(9), 820–835.

[7] García, A. R., & Piccari, L. (2022). Emerging phenotypes of pulmonary hypertension associated with COPD: A field guide. Current Opinion in Pulmonary Medicine, 28(4), 343–351.

[8] Seimetz, M., Parajuli, N., Pichl, A., et al. (2011). Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell, 147(2), 293–305.

[9] Zeder, K., Marsh, L. M., Avian, A., et al. (2024). Compartment-specific remodeling patterns in end-stage chronic obstructive pulmonary disease with and without severe pulmonary hypertension. The Journal of Heart and Lung Transplantation, 43(7), 1090–1101.

[10] Zhou, Y. H., Gallins, P. J., Pace, R. G., et al. (2023). Genetic modifiers of cystic fibrosis lung disease severity: Whole-genome analysis of 7840 patients. American Journal of Respiratory and Critical Care Medicine, 207(10), 1324–1333.

[11] Lee, J. M., Huang, Y., Orth, M., et al. (2022). Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. American Journal of Human Genetics, 109(5), 885–899.

[12] Sankaran, V. G., Menne, T. F., Xu, J., et al. (2008). Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science, 322(5909), 1839–1842.

[13] Frangoul, H., Altshuler, D., Cappellini, M. D., et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252–260.

[14] Sakornsakolpat, P., Prokopenko, D., Lamontagne, M., et al. (2019). Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nature Genetics, 51(3), 494–505.

[15] Shrine, N., Guyatt, A. L., Erzurumluoglu, A. M., et al. (2019). New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nature Genetics, 51(3), 481–493.

[16] Shrine, N., Izquierdo, A. G., Chen, J., et al. (2023). Multi-ancestry genome-wide association analyses improve resolution of genes and pathways influencing lung function and chronic obstructive pulmonary disease risk. Nature Genetics, 55(3), 410–422.

[17] Moll, M., Sakornsakolpat, P., Shrine, N., et al. (2020). Chronic obstructive pulmonary disease and related phenotypes: Polygenic risk scores in population-based and case-control cohorts. The Lancet Respiratory Medicine, 8(7), 696–708.

[18] Pirruccello, J. P., Di Achille, P., Naufal, V., et al. (2022). Genetic analysis of right heart structure and function in 40,000 people. Nature Genetics, 54(6), 792–803.

[19] Wainstein, P., Jain, D., Zheng, Z., et al. (2022). Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data. Nature Genetics, 54(3), 263–273.

[20] Wainstein, P., Zhang, Y., Swartzentruber, J., et al. (2026). Estimation and mapping of the missing heritability of human phenotypes. Nature, 649(7976), 1219–1227.

[21] Kim, W., Hecker, J., Barr, R. G., et al. (2022). Assessing the contribution of rare genetic variants to phenotypes of chronic obstructive pulmonary disease using whole-genome sequence data. Human Molecular Genetics, 31(22), 3873–3885.

[22] Qiao, D., Lange, C., Beaty, T. H., et al. (2016). Exome sequencing analysis in severe, early-onset chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 193(12), 1353–1363.

[23] Qiao, D., Ameli, A., Prokopenko, D., et al. (2018). Whole exome sequencing analysis in severe chronic obstructive pulmonary disease. Human Molecular Genetics, 27(21), 3801–3812.

[24] Rhodes, C. J., Batai, K., Bleda, M., et al. (2019). Genetic determinants of risk in pulmonary arterial hypertension: International genome-wide association studies and meta-analysis. The Lancet Respiratory Medicine, 7(3), 227–238.

[25] Verma, A., Huffman, J. E., Rodriguez, A., et al. (2024). Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. Science, 385(6706), eadj1182.

[26] Aung, N., Vargas, J. D., Yang, C., et al. (2022). Genome-wide association analysis reveals insights into the genetic architecture of right ventricular structure and function. Nature Genetics, 54(6), 783–791.

[27] Harbaum, L., Hennigs, J. K., Pott, J., et al. (2025). Sex-specific genetic determinants of right ventricular structure and function. American Journal of Respiratory and Critical Care Medicine, 211(1), 113–123.

[28] Foris, V., Kim, K., Qian, Y., et al. (2025). Gene-based rare variant testing in vascular measures in Cudgen. American Journal of Respiratory and Critical Care Medicine, 211(Suppl.), A6142.

[29] Harder, E. M., Nardelli, P., Pistenmaa, C. L., et al. (2024). Preacinar arterial dilation mediates outcomes of quantitative interstitial abnormalities in the Cudgen Study. American Journal of Respiratory and Critical Care Medicine, 210(9), 1132–1142.

[30] Evans, J. D. W., Girerd, B., Montani, D., et al. (2016). BMPR2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis. The Lancet Respiratory Medicine, 4(2), 129–137.